This Week in Managed Care—Modifiable Risk Factors of Cancer and Other Health News

Managed Care Cast

Every week, The American Journal of Managed Care® (AJMC®) recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care news included a study demonstrating that diabetes drug canagliflozin cuts the risk of renal failure and death; the FDA approving the first targeted therapy for metastatic bladder cancer; approximately half of all cancer deaths are attributable to modifiable risk factors. Read more about the stories in this podcast: CREDENCE: Canagliflozin Cuts Risk of Renal Failure, Death 30% in Patients With Type 2 Diabetes, CKD: https://www.ajmc.com/newsroom/credence-canagliflozin-cuts-risk-of-renal-failure-death-30-in-patients-with-type-2-diabetes-ckd FDA Approves Erdafitinib, First Targeted Therapy for Metastatic Bladder Cancer: https://www.ajmc.com/newsroom/fda-approves-erdafitinib-first-targeted-therapy-for-metastatic-bladder-cancer Nearly Half of Cancer Deaths Attributable to Modifiable Risk Factors: https://www.ajmc.com/newsroom/nearly-half-of-cancer-deaths-attributable-to-modifiable-risk-factors Panelists Offer an Insider Perspective of the Unstable Future of Genetic Testing Reimbursement: https://www.ajmc.com/conferences/flasco-2019/panelists-offer-an-insider-perspective-of-the-unstable-future-of-genetic-testing-reimbursement FLASCO Spring Session 2019: https://www.ajmc.com/conferences/flasco-2019 Deaths Among Opioid Users: Impact of Potential Inappropriate Prescribing Practices: https://www.ajmc.com/journals/issue/2019/2019-vol25-n4/deaths-among-opioid-users-impact-of-potential-inappropriate-prescribing-practices The American Journal of Managed Care—April 2019: https://www.ajmc.com/journals/issue/2019/2019-vol25-n4